Acer Therapeutics Inc. – NASDAQ:ACER
Founder-led company
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Acer Therapeutics stock price monthly change
-20.20%
month
Acer Therapeutics stock price quarterly change
-9.22%
quarter
Acer Therapeutics stock price yearly change
-44.07%
year
Acer Therapeutics key metrics
Market Cap | N/A |
Enterprise value | 15.36M |
P/E | -0.56 |
EV/Sales | N/A |
EV/EBITDA | -0.40 |
Price/Sales | N/A |
Price/Book | -0.91 |
PEG ratio | 0.01 |
EPS | -2.85 |
Revenue | N/A |
EBITDA | -9.91M |
Income | -60.92M |
Revenue Q/Q | N/A |
Revenue Y/Y | 3.27% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAcer Therapeutics stock price history
Acer Therapeutics stock forecast
Acer Therapeutics financial statements
| Dec 2022 | 0 | -11.23M | |
|---|---|---|---|
| Mar 2023 | 0 | -26.85M | |
| Jun 2023 | 0 | -8.09M | |
| Sep 2023 | 371.79K | -14.73M | -3962.25% |
| 2025 | 109.94M | 27.89M | 25.37% |
|---|
Analysts Price target
Financials & Ratios estimates
| Dec 2022 | 11624226 | 28.38M | 244.19% |
|---|---|---|---|
| Mar 2023 | 15672096 | 41.78M | 266.62% |
| Jun 2023 | 14648276 | 47.89M | 326.96% |
| Sep 2023 | 14002065 | 61.74M | 440.99% |
| Dec 2022 | -8.29M | -135.33K | 4.38M |
|---|---|---|---|
| Mar 2023 | -9.01M | -3.06K | 13.07M |
| Jun 2023 | -5.50M | 0 | 677.62K |
| Sep 2023 | -15.99M | 0 | 6.17M |
Acer Therapeutics alternative data
| Aug 2023 | 33 |
|---|---|
| Sep 2023 | 30 |
| Oct 2023 | 30 |
| Nov 2023 | 30 |
| Dec 2023 | 30 |
| Jan 2024 | 30 |
| Feb 2024 | 30 |
| Mar 2024 | 30 |
| Apr 2024 | 30 |
| May 2024 | 30 |
| Jun 2024 | 30 |
| Jul 2024 | 30 |
Acer Therapeutics other data
9.95%
-0.32%
of ACER is owned by hedge funds
1.41M
-49.99K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2021 | 10000 | 0 |
| Nov 2022 | 1229508 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | ASELAGE STEVE director | Common Stock | 409,836 | $1.22 | $500,000 | ||
Purchase | SCHELLING CHRIS director, 10 percent owner, off.. | Common Stock | 819,672 | $1.22 | $1,000,000 | ||
Purchase | ASELAGE STEVE director | Common Stock | 7,984 | $2.04 | $16,287 | ||
Purchase | ASELAGE STEVE director | Common Stock | 2,016 | $2.15 | $4,334 | ||
Purchase | JOSEPH DONALD officer: Chief Le.. | Common Stock | 14,285 | $3.5 | $49,998 | ||
Purchase | SCHELLING CHRIS director, 10 percent owner, off.. | Common Stock | 142,857 | $3.5 | $500,000 | ||
Purchase | ASELAGE STEVE director | Common Stock | 45,000 | $3.5 | $157,500 | ||
Purchase | DUNN JOHN MICHAEL director | Common Stock | 21,428 | $3.5 | $74,998 | ||
Purchase | ASELAGE STEVE director | Common Stock | 5,000 | $3.72 | $18,580 | ||
Purchase | TVM LIFE SCIENCE VENTURES VII L.P. director, 10 percent owner | Common Stock | 275,000 | $18 | $4,950,000 |
| Patent |
|---|
Application Filling date: 3 Dec 2021 Issue date: 9 Jun 2022 |
Grant Filling date: 9 Mar 2021 Issue date: 21 Dec 2021 |
Grant Filling date: 9 Mar 2021 Issue date: 26 Oct 2021 |
Application Filling date: 9 Mar 2021 Issue date: 22 Jul 2021 |
Application Filling date: 9 Mar 2021 Issue date: 24 Jun 2021 |
Application Filling date: 17 Jan 2020 Issue date: 20 Aug 2020 |
| Quarter | Transcript |
|---|---|
| Q2 2016 12 Aug 2016 | Q2 2016 Earnings Call Transcript |
| Q1 2016 13 May 2016 | Q1 2016 Earnings Call Transcript |
| Q4 2015 16 Mar 2016 | Q4 2015 Earnings Call Transcript |
| Q2 2015 13 Aug 2015 | Q2 2015 Earnings Call Transcript |
-
When is Acer Therapeutics's next earnings date?
Unfortunately, Acer Therapeutics's (ACER) next earnings date is currently unknown.
-
Does Acer Therapeutics pay dividends?
No, Acer Therapeutics does not pay dividends.
-
What is Acer Therapeutics's stock symbol?
Acer Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "ACER".
-
What is Acer Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Acer Therapeutics?
Shares of Acer Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Acer Therapeutics's key executives?
Acer Therapeutics's management team includes the following people:
- Mr. Christopher Schelling Founder, Pres, Chief Executive Officer & Director(age: 49, pay: $675,800)
- Mr. Harry S. Palmin Chief Operating Officer & Chief Financial Officer(age: 55, pay: $535,360)
- Mr. Donald R. Joseph J.D. Chief Legal Officer & Sec.(age: 71, pay: $490,280)
-
Is Acer Therapeutics founder-led company?
Yes, Acer Therapeutics is a company led by its founder Mr. Christopher Schelling.
-
How many employees does Acer Therapeutics have?
As Jul 2024, Acer Therapeutics employs 30 workers.
-
When Acer Therapeutics went public?
Acer Therapeutics Inc. is publicly traded company for more then 21 years since IPO on 14 Apr 2004.
-
What is Acer Therapeutics's official website?
The official website for Acer Therapeutics is acertx.com.
-
Where are Acer Therapeutics's headquarters?
Acer Therapeutics is headquartered at One Gateway Center, Newton, MA.
-
How can i contact Acer Therapeutics?
Acer Therapeutics's mailing address is One Gateway Center, Newton, MA and company can be reached via phone at +84 49026100.
Acer Therapeutics company profile:
Acer Therapeutics Inc.
acertx.comExchange:
NASDAQ
Full time employees:
30
Industry:
Biotechnology
Sector:
Healthcare
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.
One Gateway Center
Newton, MA 02458
Newton, MA 02458
CIK: 0001069308
ISIN: US00444P1084
CUSIP: 00444P108
